Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 3/20 | 0.39 |
| ▸ | BACE1 | P56817 | 5/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.34 |
| ▸ | CTSB | P07858 | 3/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.33 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2375532 | 0.87 | SCN9A (0.43) | SCN9ABACE1AKR1B1MAPK8BACE2 | |
| SCHEMBL2376665 | 0.82 | BACE1 (0.36) | SCN9ABACE1AKR1B1KCNH2 | |
| SCHEMBL1828658 | 0.81 | AKR1B1 (0.38) | BACE1AKR1B1KCNH2 | |
| SCHEMBL2376958 | 0.81 | SCN9A (0.37) | SCN9ABACE1AKR1B1 | |
| SCHEMBL2377903 | 0.79 | AKR1B1 (0.37) | BACE1AKR1B1BACE2KCNH2 | |
| SCHEMBL2376310 | 0.79 | AKR1B1 (0.37) | BACE1AKR1B1BACE2KCNH2 | |
| SCHEMBL12245589 | 0.79 | AKR1B1 (0.37) | BACE1AKR1B1BACE2KCNH2 | |
| SCHEMBL2376466 | 0.78 | BACE1 (0.47) | BACE1AKR1B1KCNH2 | |
| SCHEMBL12246268 | 0.78 | BACE1 (0.41) | BACE1AKR1B1KCNH2 | |
| SCHEMBL2375239 | 0.77 | BACE1 (0.42) | BACE1AKR1B1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921359-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8921359-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8450308-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450308-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | VITAE PHARMACEUTICALS, INC. (US) | 2011-09-08 | — | — | US | disclosed |
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | VITAE PHARMACEUTICALS, INC. (US) | 2011-09-08 | — | — | US | disclosed |
| WO-2010021680-A2 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | BACE1, BACE2, APP | SCN9A 234/4885BACE1 1/4885AKR1B1 2656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.